A CT ordered “with and without contrast” means the patient gets scanned twice: once before any contrast dye is injected, and once after. This dual-phase approach is reserved for a narrow set of clinical scenarios where comparing the two images side by side provides diagnostic information that neither scan alone can deliver. For most imaging needs, a single-phase scan (either with or without contrast) is sufficient, and ordering both phases unnecessarily doubles the radiation dose.
Why Two Scans Instead of One
The core logic behind a with-and-without study is measurement. Certain diagnoses depend on seeing how much a structure “lights up” after contrast enters it. A kidney mass, for example, might look identical to a simple cyst on a contrast-enhanced image alone. But if you can compare its density before and after contrast injection, you can measure the change. A mass that increases by more than 20 Hounsfield units (the standard density measurement on CT) is enhancing, which means it has a blood supply and needs further workup. A simple cyst shows no enhancement at all. Without that pre-contrast baseline, you cannot make that calculation.
The same principle applies to adrenal nodules. A non-contrast scan measures the nodule’s baseline fat content (fat-rich nodules are almost always benign), while the post-contrast scan shows how the nodule takes up and washes out the dye. Together, these phases can distinguish a harmless adenoma from a metastasis without requiring a biopsy.
Specific Indications for With and Without Contrast
Johns Hopkins imaging guidelines limit dual-phase abdominal CT to six scenarios:
- Renal mass characterization: Determining whether a kidney lesion is a simple cyst or a solid, enhancing mass.
- Hematuria workup: Evaluating the kidneys, collecting systems, and bladder for cancer in a patient with blood in the urine.
- Adrenal nodule characterization: Determining whether an indeterminate adrenal nodule under 4 cm is a benign adenoma or a metastasis.
- Post-stent repair surveillance: Checking for endoleak after aortic stent placement, where leaked contrast must be distinguished from pre-existing calcification or high-density material.
- GI hemorrhage: Identifying active bleeding in the bowel, where the non-contrast phase establishes a baseline so that extravasated contrast can be confidently identified on the enhanced phase.
- Focal liver mass characterization: Differentiating benign liver lesions like hemangiomas from malignant tumors based on their enhancement pattern.
Outside these situations, a dual-phase scan rarely adds diagnostic value for abdominal imaging and should generally be avoided.
When Non-Contrast CT Is Enough
Several common conditions are best evaluated without any contrast at all. Kidney stones are highly visible on non-contrast CT because of their density, and adding contrast can actually obscure small stones by filling the collecting system with bright dye. Acute head trauma and suspected brain hemorrhage are almost always imaged with non-contrast CT first, since fresh blood appears bright on the scan without any enhancement needed.
Non-contrast CT is also the standard first step for suspected stroke. The initial scan rules out hemorrhage and can estimate how much brain tissue is already damaged using scoring systems like ASPECTS (Alberta Stroke Program Early CT Score). In many stroke centers, this plain scan is the primary triage tool, especially when advanced perfusion imaging or MRI is not immediately available. Contrast-enhanced perfusion imaging may follow in specific situations, particularly when a patient presents 6 to 24 hours after symptom onset and the team needs to determine whether clot-retrieval surgery is still worthwhile.
When Contrast-Enhanced CT Is Standard
For most abdominal and pelvic imaging, IV contrast is recommended. It is essential for evaluating vascular problems like aortic dissection and aneurysm, because the dye fills the vessel lumen and makes tears, clots, or narrowing immediately visible. Infections such as appendicitis, diverticulitis, and kidney infections also show up more clearly with contrast, since inflamed tissues enhance more intensely than surrounding normal tissue. The same is true for staging cancers, locating abscesses, and assessing inflammatory bowel disease or pancreatitis.
A single contrast-enhanced phase handles these scenarios well because the clinical question is straightforward: is there abnormal enhancement, and where is it? There is no need for a pre-contrast baseline because the diagnosis does not depend on measuring a precise change in density.
IV Contrast vs. Oral Contrast
These serve different purposes and are not interchangeable. IV contrast enters the bloodstream and highlights blood vessels, organs, and anything with a blood supply. Oral contrast fills the intestines and helps distinguish bowel loops from adjacent soft tissue structures. It is particularly useful when searching for fistulas, perforations, or abscesses nestled between loops of bowel, because the opacified intestinal lumen makes “breaks” in the bowel wall easier to spot.
There is an important exception: when the clinical question involves a possible GI bleed or a bowel wall abnormality, a different type of oral contrast (called neutral contrast, often just water) is preferred. Standard bright oral contrast would mask the bleeding source or obscure the bowel wall detail you are trying to evaluate.
Kidney Function and Contrast Safety
Concerns about contrast-induced kidney injury have evolved significantly. Current guidelines from the American College of Radiology (2025 edition) indicate that patients with an eGFR of 30 or above are not at meaningfully increased risk of kidney injury from IV iodinated contrast. For patients with an eGFR between 30 and 44, the risk appears substantially lower than previously believed, and preventive IV hydration is optional, left to the ordering provider’s judgment.
Patients with an eGFR below 30 or those with acute kidney injury represent the highest-risk group. For these patients, the benefits and risks of contrast need to be weighed carefully, and preventive hydration may be appropriate. Notably, routine kidney function screening is no longer recommended for every patient before contrast administration. Testing is reserved for those with a history of kidney disease, prior acute kidney injury, dialysis, transplant, single kidney, or kidney surgery. Routine post-scan bloodwork is also unnecessary for patients who had normal kidney function at baseline.
Prior Contrast Reactions
A history of allergic-type reaction to contrast dye does not automatically rule out future contrast use. For mild prior reactions, switching to a different contrast agent is often sufficient. For moderate to severe prior reactions, the standard approach combines an alternative contrast agent with premedication: a corticosteroid and an antihistamine, ideally administered in a hospital setting equipped for emergency support. The 2025 ACR consensus emphasizes that both agent switching and premedication should be considered together, rather than relying on premedication alone, when the prior reaction was significant.
Choosing the Right Protocol
The decision tree is simpler than it might seem. Start with the clinical question. If you need to measure how much a lesion enhances (kidney mass, adrenal nodule, liver lesion characterization), you need both phases. If you need to see blood vessels, infections, or tumors, a single contrast-enhanced scan is typically sufficient. If you are looking for kidney stones, acute bleeding in the brain, or skeletal injuries, non-contrast is the right choice.
Ordering a dual-phase scan “just to be thorough” when the clinical question does not require it means the patient absorbs roughly twice the radiation dose without a corresponding diagnostic benefit. The goal is to match the protocol to the question, not to maximize the amount of data collected.